This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies.Continue
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine.
This PIL is in PDF format and so you must have a PDF reader installed on your device to read it.
Text only version for the visually impaired
Below is a text only representation of the Patient Information leaflet. The original may contain images or tables and can be viewed in PDF format using the link above. This PIL may be available from the RNIB in large print, Braille or audio CD. For further information please call the RNIB Medicine Leaflet line on 0800 198 5000. The product code(s) for this leaflet is/are: PL30306/0233, PL30306/0234, PL30306/0235.
Repaglinide 0.5mg, 1mg, 2mg Tablets
PATIENT INFORMATION LEAFLET
Repaglinide 0.5mg, 1mg and 2mg tablets
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet:
1 What Repaglinide tablets are and what they are used for
2 What you need to know before you take
3 How to take
4 Possible side effects
5 How to store
6 Contents of the pack and other information
1 What Repaglinide tablets are and what they are used for
Repaglinide tablets are an oral antidiabetic medicine containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose).
Type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces.
Repaglinide is used to control type 2 diabetes in adults as an add-on to diet and exercise: treatment is usually started if diet, exercise and weight reduction alone have not been able to control (or lower) your blood sugar. Repaglinide can also be given with metformin, another medicine for diabetes.
Repaglinide has been shown to lower the blood sugar, which helps to prevent complications from your diabetes.
2 What you need to know before you take
Do not take Repaglinide tablets:
Warning and precautions
Talk to your doctor before taking Repaglinide:
Talk to your doctor if any of the above applies to you. Repaglinide may not be suitable for you. Your doctor will advise you.
Children and adolescents
Do not take this medicine if you are under 18 years of age.
If you get a hypo (low blood sugar)
You may get a hypo (short for hypoglycaemia) if your blood sugar gets too low. This may happen:
The warning signs of a hypo may come on suddenly and can include: cold sweat; cool pale skin; headache; rapid heart beat; feeling sick; feeling very hungry; temporary changes in vision; drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating.
If your blood sugar is low or you feel a hypo coming on: eat glucose tablets or a high sugar snack or drink, then rest.
When symptoms of hypoglycaemia have disappeared or when blood sugar levels are stabilised continue Repaglinide treatment. Tell people you have diabetes and that if you pass out (become unconscious) due to a hypo, they must turn you on your side and get medical help straight away. They must not give you any food or drink. It could choke you.
If your blood sugar gets too high
Your blood sugar may get too high (hyperglycaemia). This may happen:
The warning signs of too high blood sugar appear gradually. They include: increased urination; feeling thirsty; dry skin and dry mouth. Talk to your doctor. The amount of Repaglinide, food or exercise may need to be adjusted.
Other medicines and Repaglinide
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. You can take Repaglinide with metformin, another medicine for diabetes, if your doctor prescribes it. If you take gemfibrozil (used to lower increased fat levels in the blood) you should not take Repaglinide.
Your body’s response to Repaglinide may change if you take other medicines, especially these:
Repaglinide with alcohol
Alcohol can change the ability of Repaglinide to reduce the blood sugar. Watch for signs of a hypo.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
You should not take Repaglinide if you are pregnant or you are planning to become pregnant.
You should not take Repaglinide if you are breast-feeding.
Driving and using machines
Your ability to drive or use a machine may be affected if your blood sugar is low or high. Bear in mind that you could endanger yourself or others. Please ask your doctor whether you can drive a car if you:
3 How to take
Always take this medicine exactly as your doctor has told you, Check with your doctor if you are not sure. Your doctor will work out your dose.
Do not take more Repaglinide than your doctor has recommended.
If you take more Repaglinide than you should
If you take too many tablets your blood sugar may become too low, leading to a hypo. Please see ‘If you get a hypo’ on what a hypo is and how to treat it.
If you forget to take Repaglinide
If you miss a dose, take the next dose as usual. Do not take a double dose to make up for a forgotten dose.
If you stop taking Repaglinide
Be aware that the desired effect is not achieved if you stop taking Repaglinide. Your diabetes may get worse. If any change of your treatment is necessary contact your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4 Possible side effects
Like all medicines, this medicines can cause side effects, although not everybody gets them.
Hypoglycaemia
The most frequent side effect is hypoglycaemia which may affect up to 1 in 10 patients (see If you get a hypo in section 2). Hypoglycaemic reactions are generally mild/moderate but may occasionally develop into hypoglycaemic unconsciousness or coma. If this happens, contact medical assistance immediately.
Allergy
Allergy is very rare (may affect up to 1 in 10,000 patients). Symptoms such as swelling, difficulty in breathing, rapid heartbeat, feeling dizzy and sweating could be signs of anaphylactic reaction. Contact a doctor immediately.
Other side effects
Common (may affect up to 1 in 10 patients):
Rare (may affect up to 1 in 1,000 patients):
Very rare (may affect up to 1 in 10,000 patients):
Frequency not known
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
By reporting side effects you can help provide more information on the safety of this medicine.
5 How to store
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer carton, tablet container and the blister after “EXP”. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage precautions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6 Contents of the pack and other information
What Repaglinide tablets contain
What Repaglinide tablets looks like and contents of the pack
Repaglinide tablets 0.5mg tablets are white, round, biconvex and engraved with RE on one side.
Repaglinide tablets 1mg tablets are mottled yellow, round, biconvex and engraved with RE1 on one side.
Repaglinide tablets 2mg tablets are mottled pink, round, biconvex and engraved with RE2 on one side.
Blisters (Aluminium/Aluminium).
Pack sizes: 30, 60, 90, 100,120 and 180 tablets
Plastic (polyethylene) container with desiccant canister (filled with silica gel).
Pack sizes: 100 tablets
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Manufacturer
This leaflet was last revised in January 2016
AAAI6580